Neoadjuvant Combo Immunotherapy Studied in Resectable Melanoma

FRIDAY, Oct. 28, 2022 -- For patients with resectable clinical stage III or oligometastatic stage IV melanoma, neoadjuvant relatlimab and nivolumab combination immunotherapy results in a 57 percent pathologic complete response rate, according to a...